A one-time treatment with Encoded Therapeutics’ experimental gene therapy ETX101 was generally well tolerated and associated with seizure reductions for up to one year in children with Dravet syndrome, a severe form of epilepsy that begins in infancy. That’s according to new data from the first phase of…
Zorevunersen, Stoke Therapeutics’ investigational therapy for Dravet syndrome, remained generally well tolerated and was associated with sustained seizure reductions and cognitive and behavioral improvements for up to four years. The findings come from two long-term extension studies — SWALLOWTAIL (NCT04740476) and LONGWING (ISRCTN12811235) — that followed participants…
Discussion
Tomorrow would be Austen’s 11th birthday. When I found out I was pregnant with Austen, I wasn’t sure if I was going to have another home birth or not. I loved my home birth experience with Atlas in the fall of 2013, but we were stationed in Hawaii at the…
Encoded Therapeutics announced that the first participant has been dosed in a pivotal clinical trial testing ETX101, the company’s experimental one-time gene therapy for Dravet syndrome, which is recruiting children and adolescents with this severe form of epilepsy. The pivotal study is the second part of the…
Becoming educated and informed about Dravet syndrome is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your Dravet syndrome journey.
There is no cure for Dravet syndrome yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
